Compare QNCX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNCX | ORMP |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 104.6M |
| IPO Year | 2019 | N/A |
| Metric | QNCX | ORMP |
|---|---|---|
| Price | $4.23 | $3.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 272.5K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 838.25 |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.82 |
| 52 Week High | $4.55 | $3.20 |
| Indicator | QNCX | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 74.34 |
| Support Level | $3.74 | $2.66 |
| Resistance Level | $4.30 | $2.84 |
| Average True Range (ATR) | 0.46 | 0.16 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 86.67 | 80.89 |
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.